Why Inteliquent, Pacific Biosciences of California, and Galectin Therapeutics Are Today's 3 Best Stocks

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

With the Martin Luther King Jr. holiday shortening the trading week and a very light amount of economic data on tap, the S&P 500 (SNPINDEX: ^GSPC  ) had a hard time finding traction and deciphering which way it wanted to move today.

Early fourth-quarter earnings results were the primary driver of the S&P 500, and were ultimately responsible for pushing it modestly higher.

On one hand Delta Air Lines delighted shareholders by reporting a 6% jump in revenue that was helped by a 9.4% increase in domestic revenue. The airline's profit increased as fuel costs decreased by $91 million.

Then again, health care conglomerate Johnson & Johnson (NYSE: JNJ  ) reported market-topping fourth-quarter results that included a 4.5% increase in revenue and a $0.04 EPS beat, but offered a fiscal 2014 earnings-per-share forecast of $5.75 to $5.85, at the low-end of Wall Street's forecast.

By day's end, the S&P had digested these and other earnings stories and moved higher by 5.10 points (0.28%) to close at 1,843.80, ending a two-day losing streak.

Shares of VoIP and Ethernet telecommunications service provider Inteliquent (NASDAQ: IQNT  ) led the charge, advancing 22.9% after receiving an upgrade to outperform from market perform from research firm Raymond James. This followed the appointment of Kurt Abkemeier as the company's new chief financial officer. While the appointment of a new CFO clears some near-term uncertainties at Inteliquent, the upgrade with a fresh $12 price target appears to be most responsible for today's share price jump. With close to $2 in cash per share and the company valued at just 16 times forward earnings, I would certainly say that Inteliquent could have more left in the tank.

Marching to the beat of its own drum for a second straight session was Pacific Biosciences of California (NASDAQ: PACB  )  , which rallied 19.5% despite a lack of specific news on the genetic analysis company. The entire genetic analysis sector has been abuzz since the JPMorgan Healthcare Conference last week in which Illumina unveiled a new genome sequencer, the HiSeq X Ten, that is capable of sequencing 18,000 or more human genomes annually at a cost of $1,000 per genome. The opinion from analysts is that as sequencing technologies become more affordable, their use in personalizing cancer treatments is going to explode higher. That would be music to the ears of Pacific Biosciences shareholders who have seen their company improve revenue by low double-digits in recent quarters.

Finally, clinical-stage drug developer Galectin Therapeutics (NASDAQ: GALT  ) jumped 15% after announcing a preclinical study that supports its investigational new drug application for GR-MD-02 in nonalcoholic steatohepatitis, or NASH. Specifically, hyaluronic acid, a biomarker of liver fibrosis, which is common with NASH, was reduced by 33% in animals treated with GR-MD-02 compared to untreated animals. As we've witnessed with Intercept Pharmaceuticals' recent $200-per-share move following its midstage results on obeticholic acid, there's a huge market for treating advanced NASH cases (approximately 6 million people), so these early results could be encouraging. Keep in mind, though, that how a drug responds in animal testing can be completely different from how it responds in human clinical trials. Don't get too excited just yet.

Tired of not seeing your holdings among the days top performers? Perhaps you aren't looking far enough outside the box!
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2803259, ~/Articles/ArticleHandler.aspx, 8/28/2015 1:15:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated 3 hours ago Sponsored by:
DOW 16,654.77 369.26 2.27%
S&P 500 1,987.66 47.15 2.43%
NASD 4,812.71 115.17 2.45%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/27/2015 4:35 PM
^GSPC $1987.66 Up +47.15 +2.43%
S&P 500 INDEX CAPS Rating: No stars
GALT $1.86 Down +0.00 +0.00%
Galectin Therapeut… CAPS Rating: *
IQNT $18.79 Down -0.01 -0.05%
Inteliquent CAPS Rating: *****
PACB $4.86 Up +0.28 +6.11%
Pacific Bioscience… CAPS Rating: **
JNJ $96.22 Up +1.11 +1.17%
Johnson & Johnson CAPS Rating: ****